2017 NCCN Hematologic Malignancies Congress

Hematologic Malignancies
Leukemia

Clinical Relevance of Minimal Residual Disease Monitoring Limited in Acute Myeloid Leukemia

Although a majority of major cancer centers may test for minimal residual disease (MRD), a recent survey conducted by researchers at Moffitt Cancer Center, Tampa, Florida, suggests most oncologists r...

Hematologic Malignancies
Lymphoma

New Options for the Management of Hodgkin Lymphoma

With the vast majority of patients cured with primary therapy, classical Hodgkin lymphoma is largely a success story. For the 10% to 20% of patients who either relapse or are refractory to front-line ...

Hematologic Malignancies
Leukemia

Sequencing Therapy in Chronic Lymphocytic Leukemia

Although the indications to initiate treatment for chronic lymphocytic leukemia (CLL) have not changed, determining the optimal first-line treatment and sequence of therapies once treatment has begun ...

Survivorship
Lymphoma

Life After Treatment: Managing Lymphoma Survivors

According to Surveillance, Epidemiology, and End Results (SEER) data, patients with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) have 5-year survival rates of 86% and 71%, respectively.1 Although t...

Multiple Myeloma

Management of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

The treatment paradigm for multiple myeloma has changed dramatically in the past decade with the availability of several efficacious agents in various drug classes. At the National Comprehensive Cance...

Leukemia

Immunotherapeutic Approaches for B-Cell Acute Lymphocytic Leukemia

New therapeutic agents for acute lymphocytic leukemia (ALL) have led to dramatic improvement in remission rates, but questions concerning the proper sequencing and combination of these agents remain. ...

leukemia

Bruno C. Medeiros, MD, on AML: Targeted Treatment

Bruno C. Medeiros, MD, of Stanford Cancer Institute, discusses emerging novel agents and targeted molecular abnormalities in the management of acute myeloid leukemia.

lymphoma

Jane N. Winter, MD, on Follicular Lymphoma: Treatment Updates

Jane N. Winter, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of novel targeted therapies for newly diagnosed and relapsed/refractory follicular ...

lymphoma

Ranjana H. Advani, MD, on Hodgkin Lymphoma: New Management Options

Ranjana H. Advani, MD, of Stanford Cancer Institute, discusses the novel immunomodulatory agents used to manage patients with relapsed or refractory Hodgkin lymphoma.

lymphoma

Sharyn L. Kurtz, PA-C, MPAS, MA, on Managing Lymphoma Survivors

Sharyn L. Kurtz, PA-C, MPAS, MA, of Dana-Farber Cancer Institute, discusses the long-term side effects associated with curative treatments for Hodgkin lymphoma and non-Hodgkin lymphoma and how to deve...

leukemia

David G. Maloney, MD, PhD, on ALL: New Therapeutic Agents

David G. Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, reviews the clinical data and ongoing trials evaluating immunotherapy in the setting of relapsed or refractory acute lymphocyt...

leukemia

William G. Wierda, MD, PhD, on CLL: How to Sequence Therapy

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses sequencing therapy in patients with relapsed/refractory CLL/SLL based on prior treatment and the presence of...

hematologic malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms: Managing PV and ET

Ruben A. Mesa, MD, of The University of Texas Health San Antonio Cancer Center, discusses the role of JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia and how to develop ind...

Advertisement

Advertisement



Advertisement